Kelly Bilodeau

3 days ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. When the Lupus Research Alliance formed in 1999, treatment options for the condition were scarce. Doctors relied on a selection of repurposed drugs, antimalarials, steroids and chemotherapies to slow the inflammatory autoimmune disease, said Albert Roy, CEO and president of the LRA and its clinical research affiliate, Lupus Therapeutics. Now, game-changing cell therapy treatments may be around the corner.

1 week ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. After facing market headwinds in recent years, the biopharma industry finally had some wind at its back in 2024. Jumps in funding and R&D expenditures as well as a continued shift in innovation toward emerging biopharma companies helped fuel the resurgence, according to a new report from the IQVIA Institute for Human Data Science.

2 weeks ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in $27 million in net sales in the first three months of the year — beating Wall Street sales expectations and analyst predictions. Still, its strong debut doesn’t erase uncertainty around the drug, which just stumbled in the clinic, as BMS looks to answer high-stakes questions about its long-term market potential.

1 month ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. A birth control pill for men is progressing through the clinic after clearing a safety hurdle in its first human trial. The drug, which its developer YourChoice Therapeutics claims is the only non-hormonal male birth control pill in human studies, is in the midst of a second trial, putting it in contention to become the first oral contraceptive for men.

1 month ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy community. The patient died from acute liver failure , the only FDA-approved gene therapy for DMD. Its maker, Sarepta Therapeutics, the possibility that the treatment, which uses an adeno-associated virus vector to deliver its therapeutic gene payload, may have contributed to the fatality.